Michael L Beshiri, Brian J Capaldo, Ross Lake, Anson T Ku, Danielle Burner, Caitlin M Tice, Crystal Tran, Julianna Kostas, Aian Neil Alilin, Juan Juan Yin, Supreet Agarwal, Samantha A Morris, Fatima H Karzai, Tamara L Lotan, William L Dahut, Adam G Sowalsky, Kathleen Kelly
To resist lineage-dependent therapies such as androgen receptor inhibition, prostate luminal epithelial adenocarcinoma cells often adopt a stem-like state resulting in lineage-plasticity and phenotypic heterogeneity. Castrate resistant prostate adenocarcinoma can transition to neuroendocrine and occasionally to amphicrine, co-expressed luminal and neuroendocrine, phenotypes. We developed CRPC patient-derived organoid models that preserve heterogeneity of the originating tumor, including an amphicrine model displaying a range of luminal and neuroendocrine phenotypes...
April 2, 2024: Stem Cells